Bioregulators and longevity medicine: separating signal from hype

What did @theregendoc actually say?

The creator visited a Japanese longevity doctor, Dr. Takuji Shirasawa, and came back with some sweeping claims. According to the video, bioregulators derived from porcine tissue can treat "bipolar disorder, Alzheimer's, Parkinson's, autism, even end stage liver cirrhosis, chronic kidney disease" and "type 1 diabetes." The creator also argues that Western medicine is systematically ignoring four decades of Russian peptide research, and frames bioregulators as a form of regenerative medicine that helps the body "repair its own healing systems." On top of all that, the creator says they're now using bioregulators themselves for a newly diagnosed case of ADHD, and they're offering to facilitate patient travel to Japan for treatment.

Does the science back this up?

Partially, and only at the most basic level. Bioregulators, sometimes called peptide bioregulators or cytomedins, are short-chain peptides originally developed in Soviet-era Russia by researchers like Vladimir Khavinson. The underlying concept is real: these compounds interact with gene expression at the epigenetic level, and there is published research supporting their role in cellular regulation. Khavinson et al. (2013, Bulletin of Experimental Biology and Medicine) documented effects of pineal and thymic peptide bioregulators on aging biomarkers in animal and limited human studies. That research exists and is worth examining. But the jump from "may support cellular aging processes" to "treats Alzheimer's, Parkinson's, type 1 diabetes, and autism" is not a small step. It is a canyon. No randomized controlled trials at scale support those specific therapeutic claims. Most Khavinson-era studies were small, lacked placebo controls by modern standards, and have not been independently replicated in Western peer-reviewed journals. The science is intriguing but extremely preliminary for the disease states named in this video.

What did they get wrong (or right)?

They got the existence of Russian peptide bioregulator research right. Dismissing Khavinson's body of work entirely would be intellectually lazy, and the creator is fair to point that out. The Western medical establishment does have a bias toward research published in English-language journals, and that is a legitimate critique worth making.

What they got badly wrong is the disease claim list. Saying bioregulators can treat end-stage liver cirrhosis, type 1 diabetes (an autoimmune condition requiring insulin replacement), and Alzheimer's without qualifying those as experimental, anecdotal, or unproven is not just imprecise. It is potentially dangerous. Patients with those conditions may delay evidence-based care. The creator also conflates a single doctor's clinical approach with validated treatment protocols, which is a meaningful distinction. One prolific author with 300 books is not the same thing as peer-reviewed consensus.

• The ADHD self-diagnosis via EEG and qEEG is plausible as a diagnostic tool, but qEEG-guided ADHD diagnosis remains controversial (Snyder et al., 2015, Neurotherapeutics).
• "Virtual endoscopy" is a real imaging technique, but its use as described here goes beyond standard clinical application.

What should you actually know?

Peptide bioregulators are not approved by the FDA for any of the conditions named in this video. That does not automatically make them ineffective, but it means there is no regulatory safety net for patients who pursue them, especially abroad. Traveling to another country for treatment of Alzheimer's or type 1 diabetes based on a TikTok video and one doctor's assessment carries real risk, including delayed standard care, unknown quality control on compounds used, and no legal recourse if something goes wrong.

The creator says they are "happy to facilitate" patient travel to Japan, which raises a straightforward conflict-of-interest question that viewers deserve to think about. If you have a hard-to-treat condition, the answer is not necessarily a flight to Tokyo. It may be a second opinion at an academic medical center, enrollment in a clinical trial, or consultation with a specialist who follows current evidence. The promise here may be real one day. Right now, the evidence does not match the claims being made.